株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

CZ BioMed Corpの製品パイプライン分析

CZ BioMed Corp - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 256005
出版日 ページ情報 英文 26 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
CZ BioMed Corpの製品パイプライン分析 CZ BioMed Corp - Product Pipeline Review - 2015
出版日: 2015年12月23日 ページ情報: 英文 26 Pages
概要

CZ BioMed Corpは米国に本社を置くバイオテクノロジー企業です。腫瘍細胞を消滅させるよう遺伝子操作された感冒ウイルス(RVLYSIS)の創薬・開発、商品化を行っています。RVLYSISは、癌細胞を消滅させ、腫瘍細胞のアポトーシスを誘因する機能を有しています。

当レポートでは、CZ BioMed Corp における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

CZ BioMed Corp の基本情報

  • CZ BioMed Corp の概要
  • 主要情報
  • 企業情報

CZ BioMed Corp :R&Dの概要

  • 主な治療範囲

CZ BioMed Corp :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

CZ BioMed Corp :パイプライン製品の概況

  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ

CZ BioMed Corp :薬剤プロファイル

  • Brvlysis
  • Cervlysis
  • Corvlysis
  • Hervlysis
  • Lurvlysis
  • Mervlysis
  • Ovarvlysis
  • Panrvlysis
  • Prorvlysis

CZ BioMed Corp :パイプライン分析

  • 投与経路別
  • 分子タイプ別

CZ BioMed Corp :最新のパイプライン状況

CZ BioMed Corp :本社と子会社の所在地

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07922CDB

Summary

Global Markets Direct's, 'CZ BioMed Corp - Product Pipeline Review - 2015', provides an overview of the CZ BioMed Corp's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CZ BioMed Corp's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of CZ BioMed Corp including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of CZ BioMed Corp's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the CZ BioMed Corp's pipeline products

Reasons to buy

  • Evaluate CZ BioMed Corp's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of CZ BioMed Corp in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the CZ BioMed Corp's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of CZ BioMed Corp and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of CZ BioMed Corp
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of CZ BioMed Corp and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • CZ BioMed Corp Snapshot
    • CZ BioMed Corp Overview
    • Key Information
    • Key Facts
  • CZ BioMed Corp - Research and Development Overview
    • Key Therapeutic Areas
  • CZ BioMed Corp - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • CZ BioMed Corp - Pipeline Products Glance
    • CZ BioMed Corp - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • CZ BioMed Corp - Drug Profiles
    • Brvlysis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cervlysis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Corvlysis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Hervlysis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Lurvlysis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Mervlysis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Ovarvlysis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Prorvlysis
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • CZ BioMed Corp - Pipeline Analysis
    • CZ BioMed Corp - Pipeline Products by Route of Administration
    • CZ BioMed Corp - Pipeline Products by Molecule Type
  • CZ BioMed Corp - Recent Pipeline Updates
  • CZ BioMed Corp - Dormant Projects
  • CZ BioMed Corp - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • CZ BioMed Corp, Key Information
  • CZ BioMed Corp, Key Facts
  • CZ BioMed Corp - Pipeline by Indication, 2015
  • CZ BioMed Corp - Pipeline by Stage of Development, 2015
  • CZ BioMed Corp - Monotherapy Products in Pipeline, 2015
  • CZ BioMed Corp - Preclinical, 2015
  • CZ BioMed Corp - Pipeline by Route of Administration, 2015
  • CZ BioMed Corp - Pipeline by Molecule Type, 2015
  • CZ BioMed Corp - Recent Pipeline Updates, 2015
  • CZ BioMed Corp - Dormant Developmental Projects,2015

List of Figures

  • CZ BioMed Corp - Pipeline by Top 10 Indication, 2015
Back to Top